Heron Therapeutics, Inc. (HRTX)
0.3111
-0.01
(-4.54%)
USD |
NASDAQ |
Nov 13, 16:00
0.31
0.00 (0.00%)
After-Hours: 19:59
Heron Therapeutics Enterprise Value : 171.22M for Nov. 12, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 12, 2026 | 171.22M |
| November 11, 2026 | 177.57M |
| November 10, 2026 | 180.38M |
| November 09, 2026 | 179.71M |
| November 06, 2026 | 164.97M |
| November 05, 2026 | 162.51M |
| November 04, 2026 | 166.04M |
| November 03, 2026 | 163.40M |
| November 02, 2026 | 165.37M |
| October 30, 2026 | 162.07M |
| October 29, 2026 | 165.24M |
| October 28, 2026 | 167.99M |
| October 27, 2026 | 166.59M |
| October 26, 2026 | 166.44M |
| October 23, 2026 | 166.84M |
| October 22, 2026 | 165.58M |
| October 21, 2026 | 173.67M |
| October 20, 2026 | 176.65M |
| October 19, 2026 | 177.87M |
| October 16, 2026 | 177.89M |
| October 15, 2026 | 180.83M |
| October 14, 2026 | 178.08M |
| October 13, 2026 | 183.51M |
| October 12, 2026 | 188.26M |
| October 09, 2026 | 186.45M |
| Date | Value |
|---|---|
| October 08, 2026 | 177.36M |
| October 07, 2026 | 182.31M |
| October 06, 2026 | 172.32M |
| October 05, 2026 | 179.60M |
| October 02, 2026 | 175.34M |
| October 01, 2026 | 176.92M |
| September 30, 2026 | 168.87M |
| September 29, 2026 | 164.71M |
| September 28, 2026 | 162.02M |
| September 25, 2026 | 162.48M |
| September 24, 2026 | 161.68M |
| September 23, 2026 | 161.87M |
| September 22, 2026 | 163.39M |
| September 21, 2026 | 157.89M |
| September 18, 2026 | 165.42M |
| September 17, 2026 | 166.55M |
| September 16, 2026 | 166.95M |
| September 15, 2026 | 166.23M |
| September 14, 2026 | 166.48M |
| September 11, 2026 | 166.51M |
| September 10, 2026 | 167.80M |
| September 09, 2026 | 169.83M |
| September 08, 2026 | 173.05M |
| September 04, 2026 | 171.90M |
| September 03, 2026 | 169.26M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Tonix Pharmaceuticals Holding Corp. | -99.49M |
| Karyopharm Therapeutics, Inc. | 191.67M |
| Minerva Neurosciences, Inc. | 113.30M |
| Corbus Pharmaceuticals Holdings, Inc. | -41.16M |
| Ocugen, Inc. | 300.72M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -5.006M |
| Revenue (Quarterly) | 35.25M |
| Total Expenses (Quarterly) | 40.26M |
| EPS Diluted (Quarterly) | -0.0262 |
| Gross Profit Margin (Quarterly) | 74.59% |
| Profit Margin (Quarterly) | -14.20% |
| Earnings Yield | -36.48% |
| Normalized Earnings Yield | -36.48 |